Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

World Health Organisation

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

World Hepatitis Day highlights need to reach 2030 elimination target

According to the World Hepatitis Alliance, someone dies from a viral hepatitis-related illness every 30 seconds

- PMLiVE

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’...

Avalere Health

- PMLiVE

Gilead set to acquire hepatitis specialist MYR for €1.15bn

Acquisition will see Gilead pick up HDV treatment Hepcludex

- PMLiVE

Just 20% of people living with hep C are aware of their status

WHO's hepatitis report reveals global impact of the disease

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

J&J buys firm seeking hepatitis B cure

Acquires Philadelphia-based Novira therapeutics

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Gilead Sciences

Gilead reports positive data on ‘universal’ hepatitis C regimen

Sets sights on regulatory approval for combination therapy 

- PMLiVE

First-ever World Hepatitis Summit calls for national programmes

Follows rise in hepatitis deaths for fifth consecutive year

- PMLiVE

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links